Complexation of Bi3+, Ac3+, Y3+, Lu3+, La3+ and Eu3+ with benzo-diaza-crown ether with carboxylic pendant arms
Author:
Egorova Bayirta V.1, Oshchepkov Maxim S.23, Fedorov Yury V.13, Fedorova Olga A.23, Budylin Gleb S.4, Shirshin Evgeny A.4, Kalmykov Stepan N.15
Affiliation:
1. Lomonosov Moscow State University , Chemistry Department , 119991 Leninskie Gory, 1/3, Moscow, Russian Federation 2. Mendeleev University of Chemistry and Technology of Russia , 125047 Miusskaya sqr., 9, Moscow, Russian Federation 3. A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Vavilova, 28, GSP-1, Moscow, Russian Federation 4. Lomonosov Moscow State University , Department of Physics, 119991 Leninskie Gory, 1/2, Moscow, Russian Federation 5. National Research Center “Kurchatov Institute”, 123182 Akademika Kurchatova sqr., 1, Moscow, Russian Federation
Abstract
Abstract
Polyaminopolycarboxylates are attractive ligands for binding cationic radionuclides for synthesis of radiopharmaceuticals with target delivery to tumor cells. Nowadays beta emitting Y−90 and Lu−177 are used as therapeutic agents, while Ac−225 and Bi−213 are considered as perspective for alpha therapy. In the present study new data on complexation of Y3+, Lu3+, Ac3+ and Bi3+ with 2,2’-(15-formyl-2,3,5,6,8,9,11,12-octahydrobenzo [b][1,4,10,7,13]trioxadiazacyclopentadecine-4,10- diyl)diacetic acid are presented. For ligand and complexes characterization potentiometric titration, solvent extraction, chromatography and solubility techniques were applied. The highest values of stability constants within the range of log K = 5.8 – 7.5 were found for Ac3+ and REE. Fast complex formation is established which is beneficial for practical applications in radiopharmaceutical synthesis.
Publisher
Walter de Gruyter GmbH
Subject
Physical and Theoretical Chemistry
Reference34 articles.
1. Zimmermann, R.: Nuclear Medicine: Radioactivity for Diagnosis and Therapy. EDP Sciences (2007). 2. Cordier, D., Forrer, F., Bruchertseifer, F., Morgenstern, A., Apostolidis, C., Good, S., Mueller-Brand, J., Maecke, H., Reubi, J. C., Merlo, A.: Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur. J. Nucl. Med. Mol. Imaging 37, 1335 (2010). 3. Essler, M., Gaertner, F. C., Neff, F., Blechert, B., Senekowitsch-Schmidtke, R., Bruchertseifer, F., Morgenstern, A., Seidl, C.: Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bilabelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur. J. Nucl. Med. Mol. Imaging 39, 602 (2012). 4. Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R., Murphy, K., Haberkorn, U., Morgenstern, A.: 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur. J. Nucl. Med. Mol. Imaging 41, 2106 (2014). 5. Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., Essler, M.: Preclinical evaluation of the α-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin. Cancer Res. 14, 3555 (2008).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|